Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02506933 · ClinicalTrials.gov registry record · Phase 2

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

A Phase 2 study of Chronic Lymphocytic Leukemia and Myelodysplastic Syndrome, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 2
Development phase
102
Enrollment target
3
Study locations

NCT02506933: Active Phase 2 study of Chronic Lymphocytic Leukemia and Myelodysplastic Syndrome, sponsored by City of Hope Medical Center.

NCT02506933 is a Phase 2 study of Chronic Lymphocytic Leukemia and Myelodysplastic Syndrome that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 102 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (44% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02506933, a Phase 2 study of Chronic Lymphocytic Leukemia and Myelodysplastic Syndrome, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
102 participants
Enrollment target
3
Study locations

Study Summary

This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is a virus that may reproduce and cause disease and even death in patients with lowered immune systems, such as those undergoing a hematopoietic cell transplant. By placing 3 small pieces of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) into a very safe, weakened virus called MVA, the multi-peptide CMV-MVA vaccine may be able to induce immunity (the ability to recognize and respond to an infection) to CMV. This may help to reduce both CMV complications and reduce the need for antiviral drugs in patients undergoing a donor hematopoietic cell transplant.

Primary Outcome

Cytomegalovirus (CMV) events included CMV reactivation ≥1250 CMV DNA IU/mL, CMV viremia prompting antiviral therapy, or CMV disease before day 100 after HCT.

Conditions Studied

Chronic Lymphocytic Leukemia Myelodysplastic Syndrome Hodgkin Lymphoma Lymphoblastic Lymphoma Acute Myeloid Leukemia in Remission Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Acute Lymphoblastic Leukemia in Remission Lymphadenopathy Cytomegaloviral Infection

Interventions

  • OTHER Placebo
  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Study Locations (3)

California

  • City of Hope Medical Center - Duarte

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2015-11-05
Est. Completion 2026-06-09
Phase Phase 2
City of Hope Medical Center

582 total trials

What the registry record for NCT02506933 still lists

NCT02506933 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (44% lower).

The record links to 10 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02506933 reports a single indexed study location in California, Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT02506933 about?

NCT02506933 is a clinical study titled "Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant". This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is a virus that may rep...

What is the current status of trial NCT02506933?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2015-11-05. Estimated completion is 2026-06-09.

What conditions does trial NCT02506933 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Acute Myeloid Leukemia in Remission.

What interventions are being tested in trial NCT02506933?

The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Multi-peptide CMV-Modified Vaccinia Ankara Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT02506933?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02506933 being conducted?

This trial has 3 study locations across California, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02506933's enrollment target sits among peer trials

102 61st of 187 higher than 126 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03704662 · 102 participants · NA

    Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

  • NCT04174742 · 102 participants

    Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

  • NCT04275362 · 102 participants

    Gait Analysis of a Lateral-Pivot Design Total Knee Replacement

  • NCT04541082 · 102 participants · Phase 1

    Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02506933, the US trial registry maintained by the National Library of Medicine. NCT02506933 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.